Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
暂无分享,去创建一个
[1] A. Fojo,et al. Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers. , 2023, JAMA Oncology.
[2] P. Harris,et al. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? , 2022, Frontiers in Endocrinology.
[3] C. Verschraegen,et al. A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] R. Sahoo,et al. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study , 2022, The Journal of Nuclear Medicine.
[5] V. Gebski,et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results. , 2022, Journal of Clinical Oncology.
[6] P. A. Futreal,et al. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. , 2022, JAMA oncology.
[7] J. Meyerhardt,et al. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). , 2022, Endocrine-related cancer.
[8] E. Mittra,et al. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.
[9] Jianguo Sun,et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States , 2021, JAMA network open.
[10] C. Rodríguez-Antona,et al. SUNitinib and EVOfosfamide (TH-302) in systemic treatment-naïve patients with G1/G2 metastatic pancreatic neuroendocrine tumors, the GETNE-1408 trial. , 2021, The oncologist.
[11] P. Tanis,et al. Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands , 2021, World Journal of Surgery.
[12] S. Severi,et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[13] R. García-Carbonero,et al. 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601) , 2020 .
[14] C. Scott,et al. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers , 2020, Clinical Cancer Research.
[15] M. Shah,et al. Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors , 2020, Cancer.
[16] M. de Jong,et al. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward , 2020, Current topics in medicinal chemistry.
[17] Helen X. Chen,et al. A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors , 2020, Clinical Cancer Research.
[18] J. Strosberg,et al. Gastroenteropancreatic Neuroendocrine Tumors , 2018, CA: a cancer journal for clinicians.
[19] M. Dietel,et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.
[20] A. Zalatnai,et al. Importance of Immunohistochemical Detection of Somatostatin Receptors , 2018, Pathology & Oncology Research.
[21] A. Rademaker,et al. A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659). , 2018 .
[22] Shouhao Zhou,et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.
[23] R. Salazar,et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Helen X. Chen,et al. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Królicki,et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study , 2017, Annals of Nuclear Medicine.
[26] E. U. Cidon. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future , 2017, World journal of gastrointestinal oncology.
[27] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[28] M. Tempero,et al. Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials , 2016, Pancreas.
[29] J. Bendell,et al. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers , 2016, Cancer investigation.
[30] James C Yao,et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.
[31] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[32] K. Hess,et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. , 2015, The Lancet. Oncology.
[33] Helen X. Chen,et al. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] V. Vilgrain,et al. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. , 2014, European journal of cancer.
[35] M. Ducreux,et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. , 2014, European journal of cancer.
[36] O. Abdel-Rahman. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations , 2014, Tumor Biology.
[37] P. Ruszniewski,et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.
[38] M. Papotti,et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study , 2014, BMC Cancer.
[39] A. Pandiella,et al. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors , 2014, Cancer and Metastasis Reviews.
[40] L. Mariani,et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[41] R. Salazar,et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). , 2013, European journal of cancer.
[42] R. Mayer,et al. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors , 2013, Cancer Chemotherapy and Pharmacology.
[43] J. Turner,et al. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. , 2012, Cancer biotherapy & radiopharmaceuticals.
[44] Jeffrey W. Clark,et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] C. Rochlitz,et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] G. Kaltsas,et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours , 2012, Endocrine-related cancer.
[47] P. Ameri,et al. Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New? , 2012, Neuroendocrinology.
[48] J. Hainsworth,et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study , 2011, The Lancet.
[49] L. Królicki,et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[50] E. D. de Vries,et al. Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[51] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[52] J. Turner,et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[53] C. Croce,et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] C. Schade-Brittinger,et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] K. Hess,et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Douglas B. Evans,et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression‐free survival among patients with low‐grade neuroendocrine tumors , 2007, Cancer.
[57] W. Hiddemann,et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[58] U. Mansmann,et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] B. Ahrén,et al. Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours , 2003, The British journal of surgery.
[60] K. Öberg. Interferon in the Management of Neuroendocrine GEP-Tumors , 2000, Digestion.
[61] J. Turner,et al. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. , 2015, Cancer biotherapy & radiopharmaceuticals.
[62] T. Hobday,et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. , 2013, The oncologist.